Abiopharma

🔍 Kang Andrew (Executive)

Company: Strategy Inc (MSTR)

Report Date: 2026-06-08

Detailed Transactions and Holdings:

• Acquired 4,260 shares of Class A Common Stock (Direct)
  Date: 2026-06-08 | Code: M | equity_swap_involved: false | shares_owned_after: 72,993.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,019 shares of Class A Common Stock at $123.384 per share (Direct)
  Date: 2026-06-09 | Code: S | equity_swap_involved: false | shares_owned_after: 71,974.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 910 shares of Class A Common Stock at $124.326 per share (Direct)
  Date: 2026-06-09 | Code: S | equity_swap_involved: false | shares_owned_after: 71,064.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 20 shares of Class A Common Stock at $124.878 per share (Direct)
  Date: 2026-06-09 | Code: S | equity_swap_involved: false | shares_owned_after: 71,044.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Holds 0 shares of Series A Perpetual Strife Preferred Stock (Direct)
  Date: 2026-06-08 | Code: H | shares_owned_after: 1,500.00
• Holds 0 shares of Series A Perpetual Stretch Preferred Stock (Direct)
  Date: 2026-06-08 | Code: H | shares_owned_after: 2,800.00
• Holds 0 shares of Series A Perpetual Stride Preferred Stock (Direct)
  Date: 2026-06-08 | Code: H | shares_owned_after: 2,250.00
• Sold 4,260 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: M | equity_swap_involved: false | shares_owned_after: 4,260.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of class A common stock of Strategy Inc ("Strategy").
• F2: The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on May 2, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units on June 5, 2026 and their settlement on June 8, 2026.
• F3: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.84 to $123.82, inclusive. The reporting person undertakes to provide to Strategy, any security holder of Strategy, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
• F4: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.84 to $124.83, inclusive. The reporting person undertakes to provide to Strategy, any security holder of Strategy, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
• F5: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.85 to $124.94, inclusive. The reporting person undertakes to provide to Strategy, any security holder of Strategy, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
• F6: The remaining 4,260 restricted stock units will vest on June 5, 2027.